Proactive Research analyst Ed Stacey presents his analysis on Oxford Cannabinoid Technologies (OCT) is a UK-based pharmaceutical company specialising in drug development from cannabinoids (compounds derived from cannabis).
The company aims to become a leader in developing licensed prescription medicines that target the endocannabinoid system with a primary focus on the pain relief market.
This market is estimated to be worth over £40 billion by 2027, which is the timeline of our forecast to commercialisation of the first drug to be produced by OCT. We provide an overview of the market and of our timeline expectations on p6 and p7.
source